Furthermore, NRP1, a novel immune checkpoint, selectively affects the production of T cell memory precursors during antitumor immune response in a cell-intrinsic manner, suggesting that NPR1 combined with immune checkpoint blockade therapy can effectively clear tumors, enabling the combined blockade of NRP1 and PD1 and contribute to more positive clinical outcome for tumor patients [44]. This evidence concerns the gene NPR1 and neoplasm.